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Clinical practice reveals that therapy with angiogenesis inhibitors often does not prolong survival of cancer
patients for more than months, because tumors elicit evasive resistance. In this issue of Cancer Cell, two
papers report that VEGF inhibitors reduce primary tumor growth but promote tumor invasiveness andmetas-
tasis. These perplexing findings help to explain resistance to these drugs but raise pertinent questions of how
to best treat cancer patients with antiangiogenic medicine in the future. We discuss here how VEGF inhibitors
can induce such divergent effects on primary tumor growth and metastasis.Rooted in the belief that blocking vessel supply starves tumors to
death (Folkman, 1971), it has become increasingly accepted that
blocking tumor angiogenesis asmuch as possible would provide
cancer patients maximal survival benefit. Given the key impor-
tance of VEGF and its receptor VEGFR2 in angiogenesis, hopes
were raised that blocking this pathway would eradicate the
tumor vasculature and heal cancer. Indeed, the monoclonal
anti-VEGF antibody bevacizumab (Hurwitz et al., 2004; Miller
et al., 2007) and the second-generation multitargeted receptor
tyrosine kinase inhibitors (RTKIs) sunitinib (Demetri et al., 2006;
Motzer et al., 2006) and sorafenib (Abou-Alfa et al., 2006; Escud-
ier et al., 2007) have prolonged the life of numerous cancer
patients. These successes have revolutionized the face of clin-
ical oncology. However, clinical experience has also revealed
that VEGF-targeted therapy often prolongs overall survival of
cancer patients by only months, without offering enduring cure
(Kerbel, 2008). In this issue ofCancer Cell, two leading angiogen-
esis laboratories present intriguing, almost perplexing evidence
that VEGF-targeted drugs inhibit primary tumor growth yet may
shorten survival of mice by promoting tumor invasiveness and
metastasis (Ebos et al., 2009; Pa`ez-Ribes et al., 2009). These
findings help to explain evasive resistance to these drugs but
also raise a number of pertinent questions of how to best combat
cancer with antiangiogenic medicine in the future.
In most cases, metastasis, not primary tumor growth, kills the
cancer patient (Gupta and Massague, 2006). Yet in the past, the
majority of preclinical studies have focused on probing how anti-
angiogenic drugs inhibit primary tumor growth, with less attention
onmetastasis.Consistentwithpreviousfindings,Ebosetal. (2009)
and Pa`ez-Ribes et al. (2009) report that different classes of VEGF-
targeted therapies (e.g., VEGF RTKIs or anti-VEGFR2) or VEGF
gene inactivation in tumor cells inhibits primary tumor growth in
various cancer mouse models and, in some cases, provides
a survival benefit. Strikingly, however, pretreatment of healthy
mice with these VEGF inhibitors prior to intravenous inoculation
of tumor cells ‘‘conditioned’’ them to more aggressive metastasis
with shortened survival. Also, adjuvant short-term VEGF RTKI
treatment after resection of the primary tumor enhanced sponta-neous metastatic tumor burden. Furthermore, brief treatment of
spontaneous and orthotopic tumor models with VEGF inhibitors
caused a persistent switch to ‘‘vasoinvasion’’ of tumor cells,
leading to increased metastasis. At first sight, these findings are
inconsistent with previous observations that anti-VEGF reduces
metastasis and are difficult to reconcile with the prevailing dogma
that tumors, primary or metastatic, require vessel supply for
growth (discussed in Crawford and Ferrara, 2009). How can we
explain thesedivergenteffectsofVEGF-targeted therapy?Figure1
highlights a number of possible reasons.
One plausible mechanism is tumor hypoxia. The more profi-
cient an antiangiogenic agent is, the more efficiently it will prune
tumor vessels and hence cause hypoxia. Unlike normal cells,
tumor cells are much better equipped to cope with hypoxia (Bra-
himi-Horn et al., 2007). Apart from metabolic reprogramming to
glucose addiction, which allows tumor cells to generate energy
in hypoxic conditions, hypoxia-tolerant tumor cell clones are
selected, while tumor stem cells in hypoxic niches escape anti-
angiogenic treatment (Brahimi-Horn et al., 2007). Hypoxia thus
selects for moremalignant metastatic cells, which are less sensi-
tive to antiangiogenic treatment (Yu et al., 2002). In support of
this concept, treatment of mice with anti-VEGFR2 induces a shift
in glioblastoma tumor phenotype toward enhanced migration
and invasion (Kunkel et al., 2001). In addition, tumors recruit
other vascular supply mechanisms, such as mobilization of
angiocompetent bone marrow-derived cells (Grunewald et al.,
2006) or co-option of existing vasculature, that are not always
inhibited by VEGF-targeted therapy (Bergers and Hanahan,
2008). But tumor cells also are proficient in escaping the noxious
hypoxic microenvironment by switching on invasive epithelial-
mesenchymal transition (EMT) and other metastatic programs
(Brahimi-Horn et al., 2007). Recent evidence indicates that this
metastatic switch is incited by narrow changes in tumor oxygen
levels (Mazzone et al., 2009). Hence, unlike normal cells, tumor
cells tolerate hypoxia better but at the same time also more
vigorously escape hypoxia.
Ebos et al. (2009) show that pretreatment of healthy (non-
tumor-bearing) mice with VEGF inhibitors prior to intravenousCancer Cell 15, March 3, 2009 ª2009 Elsevier Inc. 167
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Figure 1. Increased Tumor Invasiveness and Metastasis Evoked by VEGF Inhibitors
(A) Tumors need blood (red) and lymphatic (green) vessels to grow.
(B and C) VEGF-targeted therapies induce primary tumor shrinkage and inhibit tumor progression but can also initiate mechanisms that increase malignancy.
EMT, epithelial-mesenchymal transition; EC, endothelial cell.
(D) As result, anti-VEGF treatment can enhance tumor invasiveness and metastasis and reduce overall survival benefit.injection of tumor cells also promotes metastasis. While the
underlying mechanisms remain to be explored, effects on tumor
cell extravasation or formation of a premetastatic niche should
be considered, to name just a few. For instance, VEGF inhibitors
are known to prune quiescent vessels in healthy tissues, which
upon withdrawal of therapy show a rapid rebound growth;
such a well-vascularized niche may promote seeding of metas-
tasizing tumor cells (Kamba et al., 2006). In addition, even in
healthy mice, these VEGF inhibitors dose-dependently induce
a chronic ‘‘inflamed’’ state characterized by elevated levels of
G-CSF, SDF1a, PlGF, SCF, IL-6, erythropoietin, osteopontin,
and other cytokines that stimulate metastasis and angiogenesis
in a VEGF-independent manner (Ebos et al., 2007); some of
these cytokines also recruit angiogenic bone marrow-derived
endothelial and myeloid progenitors that promote the formation
of a premetastatic niche (Kaplan et al., 2005). Certain subclasses
of these cells only express VEGFR1, and their recruitment will
therefore not be blocked by VEGF inhibitors with a restricted
profile (such as anti-VEGFR2) (Kaplan et al., 2005). Perhaps
these cytokines ‘‘inflame’’ the endothelium, thereby facilitating
adhesion, permeability, and egress of tumor cells from the
vasculature (Gupta and Massague, 2006). Because VEGF is168 Cancer Cell 15, March 3, 2009 ª2009 Elsevier Inc.a survival factor for endothelial cells, its inhibition can cause
vessel disintegration and render the endothelium prothrombotic,
which could also affect tumor cell lodging (Lee et al., 2007).
There could be other mechanisms that underlie, or at least fail
to counteract, metastasis in VEGF inhibitor-treated mice. For
instance, some of these agents (especially the more broad-
spectrum VEGF RTKIs, which also inhibit PDGFRb) or the cyto-
kine response they induce (in the case of osteopontin) may inhibit
coverage of tumor vessels by pericytes, which destabilizes
vessels, makes themmore leaky and immature, and hence facil-
itates intravasation of tumor cells and metastasis (Bergers and
Hanahan, 2008). Another mechanism involves vessel co-option,
whereby tumor cells ensheathe preexisting vessels and travel
alongside ‘‘oxygen pipes’’ to invade healthy tissue (Bergers
and Hanahan, 2008). This mechanism may be more relevant in
particular tumors, such as in the brain.
Are the preclinical findings by Ebos et al. and Pa`ez-Ribes et al.
of general importance? Previous studies have documented that
VEGF-targeted therapy inhibits primary tumor growth and
metastasis (Sini et al., 2008; Verheul et al., 2007). In several of
these mouse models, metastasis correlates closely with tumor
burden—i.e., the bigger the tumor, the more malignant cells
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tasis is also inhibited by anti-VEGF after resection of primary
tumors (Mizobe et al., 2008). However, others have observed
no inhibition or only negligible effects of VEGF inhibitors on
metastasis (Francia et al., 2008). The reasons for these discrep-
ancies remain speculative, but, based on the mechanisms
postulated above, one can hypothesize that quantitative and
qualitative effects of VEGF-targeted therapy may depend on
a number of variables. Thesemay include tumor-intrinsic param-
eters such as VEGF levels, vessel number and function, sprout-
ing angiogenesis versus vessel co-option, VEGF dependence of
tumor vasculature, pericyte coverage, recruitment of bone
marrow cells, oxygen tension, lymphatic versus hematogenous
metastasis, etc. or may involve differences in experimental
conditions such as type of tumor andmetastasis model, duration
of treatment, class and dose of VEGF inhibitor, monotherapy
versus combination treatment with cytotoxic or other agents,
etc. (see above). Pa`ez-Ribes et al. speculate that high VEGF
levels render tumor vessels immature and facilitate intravasation
and metastasis while inhibiting VEGF may produce a similar
overall effect on metastasis, though via qualitatively distinct
mechanisms, as explained above. Another unresolved issue is
whether metastatic tumors rely as much on angiogenesis as
primary tumors, given that metastatic tumor cells often acquire
hypoxia-tolerant properties (Brahimi-Horn et al., 2007).
Emerging clinical evidence is consistent with the findings of
Ebos et al. and Pa`ez-Ribes et al. Indeed, the invasiveness and
metastatic behavior of tumor cells after VEGF-targeted therapy
may explain why, after a transitory period of primary tumor
growth inhibition and prolongation of progression-free survival,
clinical responses do not endure and tumors relapse as more
invasive metastatic disease, thereby limiting the benefit for over-
all survival (Kerbel, 2008). Also, reports that induction of tumor
hypoxia and the systemic ‘‘inflamed’’ state is dependent on the
VEGF inhibitor dose could explain why ‘‘more’’ of a VEGF inhib-
itor, in terms of dose or potency, has not consistently been
‘‘better’’ for patient outcome, though this deserves further study
(Cannistra, 2008). Furthermore, the observation that even brief
treatment with VEGF inhibitors for only a few days suffices to
induce persistent, irreversible alterations in tumor cell invasive-
ness may explain why rapid tumor regrowth has been observed
in some cancer patients during short-term ‘‘drug holidays’’
(Batchelor et al., 2007).
These findings have pertinent implications for antiangiogene-
sis medicine and raise questions as to how they can best be
translated to the clinic. For instance, are these findings class-
specific for VEGF inhibitors alone, or do other antiangiogenic
agents induce similar prometastatic effects? New antiangio-
genic agents, such as Dll4 inhibitors, inhibit primary tumor
growth but also cause hypoxia via formation of hypoperfused
vessels (Noguera-Troise et al., 2006). VEGF inhibitors induce
vessel normalization during a particular time window (Batchelor
et al., 2007; Jain, 2005); since this process has been related to
increased drug delivery, it has been questioned whether
pretreatment of cancer patients with VEGF inhibitors would
improve chemotherapy. Do the present findings suggest that
the risk of metastasis associated with neoadjuvant VEGF-
targeted therapymay outweigh the benefit of improved cytotoxic
drug delivery? Will maintenance of VEGF-targeted therapy bebeneficial by suppressing primary tumor growth, or will it be
harmful by evoking evasive resistance? Can combination
therapy with antimetastatic medicine overcome the prometa-
static effects of VEGF inhibitors and turn them intomore effective
anticancer drugs? Intuitively, one might postulate that antiangio-
genic treatment should be initiated as early as possible in cancer,
but clinical evidence shows that, in metastatic colorectal cancer
patients, continuation of VEGF-targeted therapy even beyond
disease progression still improves clinical outcome (Grothey
et al., 2008). Future clinical studies are thus warranted to assess
the relative risk of metastasis versus the benefit of tumor starva-
tion in cancer patients and whether this differs for curable non-
metastatic versus advancedmetastatic disease. Indeed, a recent
report indicates a higher incidence of distant recurrence of
glioblastoma in patients treated with the anti-VEGF antibody
bevacizumab and chemotherapy than in patients treated with
chemotherapy alone, but overall, patients treated with the
combination therapy still lived longer (Zuniga et al., 2009).
Another question is whether combining antiangiogenic drugs
with other classes of targeted agents, such as inhibitors of the
prometastatic scatter factor/HGF receptor MET or of epidermal
growth factor receptor signaling, might help to counteract the
switch to more aggressive behavior elicited by VEGF inhibitors.
However, a recent study suggests that, contrary to predictions
by preclinical research (Stommel et al., 2007), simultaneous inhi-
bition of the VEGF and EGF pathways in combination with
chemotherapy shortens rather than prolongs progression-free
survival as compared to inhibition of the VEGF pathway alone
in combination with chemotherapy (Tol et al., 2009). It thus
remains to be determined whether other targeted agents exhibit
beneficial effects when combined with VEGF inhibitors. More-
over, development of reliable biomarkers to monitor develop-
ment of evasive resistance to antiangiogenic drugs could render
this therapy more effective (Jain, 2008). In this respect, genetic
polymorphisms in the VEGF gene were recently found to be
associated with response to anti-VEGF treatment (Schneider
et al., 2008). Hopefully, such strategies may help to identify indi-
viduals at greater risk for these undesirable adverse effects of
VEGF-targeted therapy and lead the way to possible future
tailoring of individualized antiangiogenic therapy.
Finally, are there any alternative antiangiogenic agents that
might not evoke this malignant behavior? Given that enhanced
tumor invasiveness and malignancy appear to be more severe
upon complete blockade of VEGF, could a combination or
substitution of VEGF inhibitors with agents that induce less
hypoxia (such as anti-PlGF [Fischer et al., 2007]) provide an alter-
native? Or should conceptually distinct antivascular strategies
be considered? For instance, can tumor vessel function, rather
than numbers, be targeted? A recent study shows that haplode-
ficiency of PHD2 in endothelial cells improves tumor vessel
perfusion via normalization of their endothelial layer and thereby
shifts the tumor to more benign, less invasive and metastatic
behavior (Mazzone et al., 2009), which is also more responsive
to chemotherapy (unpublished data).
In the ancient Greek myth, when Odysseus had to choose
between two life-threatening evils, Scylla and Charybdis, he
managed to avoid both. Future studies will be required to
develop strategies that will allow us to optimally exploit the
potential of VEGF inhibitors to block primary tumor growth whileCancer Cell 15, March 3, 2009 ª2009 Elsevier Inc. 169
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Minireviewat the same time suppressing prometastatic effects, without
having to choose between the evils of increased primary tumor
growth in untreated conditions and induction of metastasis in
treated conditions.
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